356 items found

Groups: Open Access Tags: 110309 Infectious Diseases CI RCT Science Policy

Filter Results
  • dataset

    r37980778c78--f97206ad2b9b0c9532b241d28f976a09

    Subgroup analyses of the efficacy endpoints.
  • dataset

    Trial characteristics: <i>A</i>. <i>Paniculata</i> versus Placebo (n = 4).

    Trial characteristics: A. Paniculata versus Placebo (n = 4).
  • dataset

    Characteristics of included trials.

    PI, plaque index; GI, gingival index; PPD, probing pocket depth; CAL, clinical attachment loss; GR, gingival recession; BOP, bleeding on probing; NA, not available; CHX,...
  • dataset

    Characteristics of included studies and participants.

    Characteristics of included studies and participants.
  • dataset

    Baseline characteristics of participants.

    Data are presented as mean±SD, median (interquartile range) or percent. Chi-square test for categorical variables, the unpaired t test or Mann-Whitney U test for continuous...
  • dataset

    r37980778c78--e2d46eb3626c102f8826434895588dfc

    PurposeThis systematic review and meta-analysis aims to assess the therapeutic and adverse effects of acupuncture for benign prostatic hyperplasia (BPH) in randomized controlled...
  • dataset

    Characteristics of included trials [ordered by study ID].

    Characteristics of included trials [ordered by study ID].
  • dataset

    r37980778c78--fed859da83a9f11c261a2a22089b3f4e

    Adverse events reported in the included trials.
  • dataset

    r37980778c78--a19c85db5d4cbd294f27f9d00cb2bc83

    Characteristics of primary trials.
  • dataset

    Summary of data on serological response rates of interventions at 6-month fol...

    Summary of data on serological response rates of interventions at 6-month follow-up.
  • dataset

    Flow chart presenting the selection of eligible studies.

    Flow chart presenting the selection of eligible studies.
  • dataset

    r37980778c78--b1ca63d5f6610601a8feda6d0c619988

    Summary of findings.
  • dataset

    Summary of the results.

    The proteasome inhibitor MG-132 down-regulates (−) the ubiquitin-proteasome pathway (UPP). AMPK-activator AICAR and proteasome inhibitor MG-132 co-treatment activates (+) the...
  • dataset

    Characteristics of Studies Included in the Meta-analysis Comparing the SMILE ...

    SMILE = small incision lenticule extraction, FS-LASIK = femtosecond laser-assisted LASIK, SE = spherical equivalent.
  • dataset

    Subgroup analysis according to the route of administration (injectable vs. or...

    Subgroup analysis according to the route of administration (injectable vs. oral) of eligible disease modifying therapies for the treatment of relapsing-remitting multiple...
  • dataset

    r37980778c78--e592b4284520a99abb904b8e48c4297e

    Characteristics of the 16 included studies.
  • dataset

    r37980778c78--fea216c3ef42258cde0ada893d854216

    Methodological quality of the included studies.
  • dataset

    r37980778c78--2d25a2eca8c947111837ae47e6f72d4a

    Laronidase for MPS I: Outcomes defined a priori and studies that evaluated them.
  • dataset

    Meta-analysis of the most frequent TEAEs with a frequency of≥5% in duloxetine...

    Meta-analysis of the most frequent TEAEs with a frequency of≥5% in duloxetine-treated patients.
  • dataset

    r37980778c78--ade22df0ce4003458169ac78b7a5c833

    ObjectivesTo assess the effectiveness and safety of Chinese herbal medicine (CHM) for the treatment of aspirin resistance (AR).MethodsA comprehensive research of seven...